medigraphic.com

2013, Number 3

<< Back Next >>

Rev Cuba Endoc 2013; 24 (3)

Rapidly evolving adrenal carcinoma

González CTM, Conesa GAI, Hernández MJC, Leal CL

Language: Spanish
References: 28
Page: 270-278
PDF size: 109.31 Kb.


ABSTRACT

Introduction: primary suprarrenal carcinoma is a highly aggressive rare carcinoma of rapid growth, with greater incidence in 40-60 years age group. The functioning carcinomas represent up to 79 % of cortical tumors that are more frequent in females, and 50 % of them clinically manifests as Cushing syndrome. The extension of the tumor to neighboring structures is common and worsens the prognosis. Mean survival rate is 2 years from the time of diagnosis, particularly when there are liver and lung metastases.
Objective: to describe the clinical characteristics, the diagnostic and therapeutic procedures in a female patient with rapidly evolving adrenal carcinoma.
Case presentation: a patient LRS, female, Caucasian, 49 years-old, with a history of blood hypertension and type 2 diabetes mellitus, who went to the hospital because of lack of metabolic control and blood hypertension. On physical examination, there were observed some signs suggestive of hypercortisolism, symptomatology that became notably acute two months later. Basal, dynamic, imaging and anatomopathological studies were made to corroborate the presumptive diagnosis. Left adrenalectomy with regional adenectomy was performed, and the diagnosis of left suprarenal carcinoma was confirmed through pathological anatomy. Few months later, the patient died from osseous metastasis in her spinal cord.
Conclusions: early recognition of symptoms and signs of adrenal hyperfunction is very important for diagnosis and timely treatment of adrenal carcinoma.


REFERENCES

  1. Stewart PM, Krone NP. The Adrenal Cortex. En: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM (eds). Williams Textbook of Endocrinology. 12th. ed. Philadelphia: Elsevier Saunder; 2011. p. 479-534.

  2. Lal G, O'Dorisio T, Mc Dougall R, Weigel RJ. Cancer of the endocrine system. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, Kastan MB, McKenna WG. Clinical Oncology. Philadelphia, PA: Elsevier; 2008. p. 1271-303.

  3. Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR Am J Roentgenol. 2008;190:1163-8.

  4. Lacroix A. Approach to the Patient with Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2010;95(11):4812-22.

  5. Alonso Z, Vargas A. Neoplasias cortico-suprarrenales funcionantes. Reporte de un caso y revisión. Revista Médica de Costa Rica y Centroamérica LXII. 2005;573:179-83.

  6. Linda NG, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol. 2003;169(1):5-11.

  7. Menéndez C, Casal F, Prieto J, Cacho L, Tuson C. Carcinoma suprarrenal. Análisis retrospectivo de cinco casos. An Med Interna. 2006;23(11):533-6.

  8. Muro GE, Losada JL, Martín A, Pérez IR. Carcinoma suprarrenal gigante. Presentación de un caso. Arch Esp Urol. 2009;62(2):12-4.

  9. Abiven G, Coste J, Groussin L. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endo & Metab. 2006;91:2650-5.

  10. Kasperlik-Zaluska A, Otto M, Cichocki A, Roslonowska E, Slowiñska-Srzednicka J, Jeske W, et al. Incidentally Discovered Adrenal Tumors: A Lesson from Observation of 1444 Patients. Horm Metab Res. 2008;40(5):338-41.

  11. William F, Young Jr. The Incidentally Discovered Adrenal Mass. N Engl J Med. 2007;356:601-10.

  12. American Joint Committee on Cancer. Adrenal. In: AJCC Cancer Staging Manual. 7th. ed. New York: Springer; 2010. p. 515-7.

  13. Fraker DL. Adrenal Tumors. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008. p. 1690-702.

  14. Rodríguez-Hermosa JI, Roig J, Ortuno P, Quiles AM, Recasens M, Codina- Cazador A. Gran tumor suprarrenal. Rev Esp Enferm Dig. 2008;100(6):363-4.

  15. Vera NV, AttanAsío RA, Chiesa LF, Elliff E, Menvielle S. Carcinoma adrenal secretor de estrógenos, a propósito de un caso. RAEM. 2009;46:84.

  16. Mir M, Ruiz-Giménez N, Zapata C, Rodríguez B, Vílchez V, Suárez C. Carcinoma suprarrenal. Presentación de un caso y revisión de la literatura. Rev Clin Esp. 2009;209(3):150-2.

  17. Mediavilla JD, López de la Torre M, Muñoz J, Sánchez MJ, Jaén F. Diversidad en la expresión clínica del carcinoma suprarrenal. Presentación de 7 casos. Endocrinología y Nutrición. 2004;51(8):82-6.

  18. Allolio B, Hahner S, Weismann D. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf). 2004;60:273-87.

  19. Fassnacht M, Johanssen S, Quinkler M; German Adrenocortical Carcinoma Registry Group; European Network for the Study of Adrenal Tumors. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009;115:243-50.

  20. Pennanen M, Raade M, Louhimo J, Sane T, Heiskanen I, Arola J, et al. Adrenocortical tumours: high CT attenuation value correlates with eosinophilia but does not discriminate lipid-poor adenomas from malignancy J Clin Pathol. 2013;66(12):1076-80.

  21. Sane T, Schalin-Jäntti C, Raade M. Is Biochemical Screening for Pheochromocytoma in Adrenal Incidentalomas Expressing Low Unenhanced Attenuation on Computed Tomography Necessary? J Clin Endocrinol Metab. 2012;97(6):2077-83.

  22. Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT, et al. Recurrence of Adrenal Cortical Carcinoma Following Resection: Surgery Alone Can Achieve Results Equal to Surgery Plus Mitotane. Ann Surg Oncol. 2010;17(1):263- 70.

  23. Wen TS, Cord S, Quan-Yang D. From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors. Journal of Surgical Oncology. 2005;89(3):186-92.

  24. Kulis T, Knezevic N, Pekez M, Kastelan D, Grkovic M, Kastelan Z. Laparoscopic Adrenalectomy: Lessons Learned from 306 Cases. J Laparoendosc Adv Surg Tech A. 2012;22(1):22-6.

  25. Zografos GN, Vasiliadis G, Farfaras AN, Aggeli C, Digalakis M. Laparoscopic surgery for malignant adrenal tumors. JSLS. 2009;13(2):196-202.

  26. Cobb W, Kercher KW, Sing RF, Heniford B. Laparoscopic adrenalectomy for malignancy. The American Journal of Surgery. 2005;189(4):405-11.

  27. Terzolo M, Angeli A, Fassnacht M. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372-80.

  28. Choi YA, Kim CK, Park BK, Kim B. Evaluation of Adrenal Metastases from Renal Cell Carcinoma and Hepatocellular Carcinoma: uUse of Delayed Contrast-enhanced CT. Radiology. 2013;266(2):514-20.




2020     |     www.medigraphic.com